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A key question for urologic practitioners is whether an apparently organ-confined prostate
cancer (PCa) is actually aggressive or not. The dilemma is to specifically identify among all
prostate tumors the very aggressive high-grade cancers that will become life-threatening
by developing extra-prostatic invasion and metastatic potential and the indolent cancers
that will never modify a patient’s life expectancy. A choice must be made between several
therapeutic options to achieve the optimal personalized management of the disease that
causes as little harm as possible to patients. Reliable clinical, biological, or pathological
markers that would enable distinctions to be made between aggressive and indolent PCas
in routine practice at the time of initial diagnosis are still lacking.The molecular mechanisms
that explain why a PCa is aggressive or not are also poorly understood. Among the potential
markers and/or actors in PCa aggressiveness, Src and other members of the Src kinase fam-
ily, are valuable candidates. Activation of Src-dependent intracellular pathways is frequently
observed in PCa. Indeed, Src is at the cross-roads of several pathways [including andro-
gen receptor (AR), TGFbeta, Bcl-2, Akt/PTEN or MAPK, and ERK . . .], and is now known
to influence some of the cellular and tissular events that accompany tumor progression:
cell proliferation, cell motility, invasion, epithelial-to-mesenchymal transition, resistance to
apoptosis, angiogenesis, neuroendocrine differentiation, and metastatic spread. Recent
work even suggests that Src could also play a part in PCa initiation in coordination with the
AR. The aim of this review is to gather data that explore the links between the Src kinase
family and PCa progression and aggressiveness.
Keywords: prostate cancer, c-Src, SFK family, tyrosine-kinase, aggressiveness, prognosis, epithelial-to-
mesenchymal transition, neuroendocrine differentiation
INTRODUCTION
Prostate cancer (PCa) is the most common non-skin cancer and
the second leading cause of cancer deaths in men from West-
ern countries. Diagnosis can be made fortuitously during the
pathological examination of prostate tissue removed because of
symptomatic benign prostate hyperplasia, but the disease is more
often discovered following prostate biopsies performed because
of elevated serum prostate-specific antigen (PSA) levels and/or
abnormal digital rectal examination. Another diagnostic scenario
is the identification of a PCa at a metastatic stage when metas-
tases (most often bone metastases) become clinically significant.
At this time, no curative treatment can be expected and the only
therapeutic options are androgen deprivation, which is achieved
by surgery (resection of the androgen-secreting testicular tis-
sue), LH–RH analogs (that block testicular androgen secretion),
and/or antiandrogens (that block androgen action on the nuclear
androgen receptor – AR). Although initially effective, androgen
deprivation usually results in an escape with the emergence of
a lethal castration-resistant PCa (CRPC). Therapeutic options are
more diverse for (apparently) localized, prostate-confined cancers;
in this situation, treatments (traditionally radical prostatectomy
and radiation therapy) are effective and given with a curative
intent. These treatments can, however, have a profound impact
on a patient’s quality of life, and clinicians have to be sure that
they are provided adequately, in particular, clinicians have to face
two interconnected risks (Table 1): (1) the risk of over-treating
a localized cancer that will never become life-threatening (the
so-called indolent PCa), and (2) the risk to ineffectively treating
an aggressive cancer (the so-called high-grade PCa). The preg-
nant problem when facing a PCa is therefore the need to have
an appropriate estimation of its aggressiveness in order to manage
the patient with the most appropriate treatment. This estimation is
currently based on clinical (organ-confined or not on digital rectal
examination), biological (PSA and/or derivatives), and patholog-
ical (Gleason score or number/proportion of invaded cores at
biopsy) criteria, but remains poorly reliable. Research studies have
therefore been performed world-wide to identify and evaluate bet-
ter criteria for assessing PCa aggressiveness. Efforts are usually
focused on molecular markers. The hypothesis is that the bet-
ter characterization of the intrinsic biological properties of the
tumor will lead to more personalized treatment. There are well-
established genetic alterations associated with PCa, such as the
upregulation of AR-signaling, the overexpression of c-Myc, the
loss of the tumor-suppressor gene Pten (and subsequent activa-
tion of the Akt pathway), and the fusion of Ets genes with upstream
AR-regulated promoter sequences (with TMPRSS2-Erg being the
most frequently observed fusion gene). Among others, the c-
Src tyrosine kinase (TKs) recently received particular attention
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Table 1 |The therapeutic stakes of prostate cancer.
Life-threatening Consequences of conventional curative treatments
(radical prostatectomy or radiation therapy)
Alternative therapeutic options
Indolent prostate cancer No Over-treatment (unjustified deterioration of quality of life) Active surveillance
Intermediate prostate
cancer
Yes Definitive cure (justified deterioration of quality of life) A currently unknown one without
deterioration of quality of life
High-grade prostate
cancer
Yes Ineffective treatment (incomplete tumor
destruction/removal and local or metastatic recurrence)
Androgen deprivation as a unique option
or within a (neo-) adjuvant association
because of its implication in several aspects of PCa initiation and
progression.
Tyrosine kinases are known to be involved in several fun-
damental physiological and pathological processes, and include
receptor (usually membrane-located) and non-receptor TKs. Src
is the prototypical member of the Src family of kinases (SFK),
which is the largest family of non-receptor TKs. The SFK fam-
ily has nine members (Blk, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, and
Yrk) that are implicated in several signal transduction pathways.
All SFK members share a similar structure: four Src homology
(SH1 to SH4) domains and a unique amino-terminal domain.
Src is the most widely studied SFK member, and high resolu-
tion crystallographic studies have revealed the complex mecha-
nisms that allow the switch from an inactive to an active state
(Figure 1). Src is essentially locked in an inactive conformation
through phosphorylation at the tyrosine Y530, which is located
in its negative C-terminal regulatory tail. This phosphorylation
is performed by the C-terminal Src kinase (Csk) and homol-
ogous enzymes. Phosphorylation of tyrosine Y419 in the SH1
kinase domain is the key event associated with protein unfold-
ing and catalytically active conformation. The transition from
the off-conformation to the on-conformation occurs upon stim-
ulation from numerous extracellular and intracellular signals.
For example, Src and other SFK members are downstream of
multiple membrane receptor TKs, including EGFR-Rc and IGF1-
Rc. Other interacting membrane proteins are G-protein coupled
receptors and integrins. Src is also known to crosstalk with sev-
eral intracellular compounds such as other non-receptor TKs,
steroid receptors, or components of fundamental kinase path-
ways (PI3K, MAPK, . . .). For example, Src is usually found within
a complex comprising two other non-receptor TKs: focal adhe-
sion kinases (FAK) and Etk. The three kinases are cross-reactive
with each other and therefore share the activation process when
one of them is activated by a specific stimulus. Overall, Src can
be regarded as a scaffolding adaptor between membrane and/or
intracellular proteins and these interactions can result in mutual
activation/repression depending on phosphorylation exchanges.
Src activation has been observed in several cancers, including PCa
(1–3), and several lines of evidence link Src and SFKs to prostate
carcinogenesis. Src is highly expressed in PCa cell lines (4–9),
as well as in the majority of PCa specimens (2, 5, 8, 10), and
has become a new therapeutic target. Src inhibitors have recently
reached the clinical development stage in managing patients with
metastatic PCa.
Src AND PROSTATE CANCER INITIATION
Prostatic intraepithelial neoplasia (PIN) is the putative precursor
lesion of PCa. Due to the difficulty in profiling small lesions, little
is known about gene expression and genetic alterations that could
account for the transition from PIN to cancer. The initiation of
PCa has, however, been linked to the loss or mutation of PTEN
and the subsequent activation of AKT-signaling (11), as well as to
Ets fusion genes (12). Alterations in AR-signaling have also been
advocated, either alone (13) or in combination with the activa-
tion of AKT-signaling (14–16). Most of these studies originated
from Witte’s laboratory and used an in vivo prostate regenera-
tion system in which prostate tissue is regenerated by combining
the embryonic urogenital sinus mesenchyme and the postnatal
prostate epithelium (12, 14–16). By specifically over-expressing
oncogenes of interest, the influence of extrinsic signals on the ini-
tiation and progression of PCa can be evaluated. As a result of Src
overexpression in many PCa specimens, the overexpression of Src
was induced in this system, either alone or in combination with
AR overexpression (17). In these experiments, while the overex-
pression of either Src alone or the AR alone did not significantly
change the prostate tubule structure, the simultaneous overexpres-
sion of the AR and Src produced sheets of undifferentiated cells
with no glandular organization, which is characteristic of a poorly-
or un-differentiated PCa. These results are consistent with those
previously obtained in the same regeneration system by chronic
exposure to paracrine FGF10 (15): induction of PIN and PCa was
achieved (15), probably through Src activation, since Src is known
to mediate FGF-signaling, while selective Src loss or inactivation
inhibited FGF10-induced PIN and PCa (18). A similar effect was
observed for Lyn, but not for Fyn, which are other members of
the SFK (18). Of interest is the fact that AR overexpression was
necessary for the oncogenic potential of wild-type Src, while a
constitutively active mutant Src (Y529F) alone phenocopied the
synergistic action of the AR and wild-type Src (17). This suggests
that the AR is able to activate Src (19, 20). This is a result that is
consistent with the detection of increased levels of activated Src in
the tumors induced by the simultaneous overexpression of the AR
and Src (17). Indeed, cross-activation between the AR and Src is
clearly advocated as a way to explain their synergy (17, 21), which
is possibly favored by a physical interaction between both proteins
(19, 20, 22) (Figure 2). The AR does indeed contain a proline-rich
zone that is affine for the Src SH3 domain and allows the formation
of an AR–Src complex (19, 20). The oncogenic properties of this
complex are also suggested by the influence of the DOC2/DAB2
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FIGURE 1 | Src activation. The activation of Src requires a switch from an
inactive to an active conformation. This corresponds to a phosphorylation
switch from a tyrosine residue located in the regulatory C-terminal tail (Y530),
which is characteristic of the inactive state, to a tyrosine residue located in
the catalytic SH1 domain (Y419). Src activation can result from various extra-
and/or intracellular signals.
(differentially expressed in ovarian cancer 2/disabled 2) protein
and its partner DAB2IP. DOC2/DAB2 and DAB2IP are considered
to be tumor-suppressor genes and are able to counteract the for-
mation and oncogenic action of the AR–Src complex by physically
interacting with Src (23, 24). It is notable that the synergy between
the AR and ETS-related gene (ERG) has also been suggested as pro-
moting PCa initiation (12). Since functional interactions between
the ERG and Src have also been reported (25), whether mutual
and possibly synergistic cross-talks between Src, the ERG, and the
AR are involved in PCa initiation should be investigated.
Src AND PROSTATE CANCER PROGRESSION
The role of Src and other SFKs in PCa progression has been
suggested by a number of demonstrations of their expression
in prostate cell lines (4–9) and PCa specimens (5, 8, 10). There
are also many reports that SFKs are abnormally activated in PCa
cells (1–3), in response to numerous and interconnected stim-
uli including neuroendocrine ligands (26–28), reactive oxygen
species (29), cytokines such as Il-8 (30, 31), growth factors like
EGF (27, 29, 32), IGF-1 (28, 33) VEGF (34, 35), or even intra-
cellular activating proteins such as FAK (36). It is notable that
all of these molecules are by themselves involved in several basic
aspects of cancer progression, including cell proliferation, adhe-
sion, migration, and invasion. SFKs can therefore be regarded as
integral components of the signal transduction pathways involved
in normal cellular growth, proliferation, migration, and survival,
all of which are processes that, if deregulated, promote tumor pro-
gression (37–39). With respect to molecular mechanisms, SFKs
have been proved to control cell proliferation through the activa-
tion of the Ras/ERK/MAPK pathway and to induce specific gene
expression programs by affecting the transcriptional activity of
several transcription factors like the TGFbeta effectors, the STAT
molecules (40). Cell adhesion and migration are also influenced
through direct interactions with key partners such as actins, inte-
grins, or kinases such as FAK (40, 41). Indeed, for several years, a
great deal of attention has been paid to the roles of Src in these
aspects because of the clinical development of Src inhibitors, such
as saracatinib (AZD0530), dasatinib, and bosutinib (42). Preclini-
cal in vitro studies demonstrated that these inhibitors, along with
others that have not yet reached clinical development play a signifi-
cant role in controlling cell proliferation, adhesion, and migration,
as well as the ability to form tumoral xenografts in immunodefi-
cient mice (Table 2). A direct role for Src has not really been
demonstrated, probably because the experimental overexpression
of Src – without activation – is unlikely to be sufficient in promot-
ing cancer progression. Correlations have in fact been suggested
between Src phosphorylation-mediated activation and cell migra-
tion (9, 36). Nevertheless, the direct inactivation of Src through
siRNA experiments has been proved to induce reduced migration
and growth in PCa cell lines (43, 44).
Other studies favor a role of Src in PCa-induced angiogenesis.
That Src is a potent actor in angiogenesis has been demonstrated
by a substantial amount of evidence. The interplay between Src
and VEGF is one of the molecular mechanisms that govern tumor-
associated angiogenesis and has also been described with respect to
PCa. In prostate cells, hypoxia-induced VEGF expression requires
Src activation, which activates Stats3 through phosphorylation
and increases HIF1alpha expression (52). Both transcription fac-
tors are then able to drive VEGF expression. Il-8 is a known
cytokine promoting angiogenesis, and this effect is mediated by
Src in prostate cells (31). Src and VEGF cooperation can be tar-
geted by the Src-specific inhibitor dasatinib (50) and several other
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FIGURE 2 | Reciprocal activation of Src and the androgen receptor
through direct physical interaction. (A) Src activation is induced by several
extracellular signals such as neuromediators produced by neighboring tumor
cells with neuroendocrine differentiation, growth factors produced by
neighboring tumor or stromal cells. Through direct physical interaction with
the AR, Src is able to phosphorylate the AR and thereby induce
ligand-independent AR activation (one of the key mechanisms of
castration-resistant prostate cancer). Molecular mechanisms include
increased AR translocation to the nucleus, decreased proteasomal
degradation, decreased interaction with co-repressors (CoR), and/or increased
acetylation. The result is the activation of AR-dependent gene expression
programs. (B) Conversely, upon ligand binding and direct physical interaction
with Src, the AR is able to induce Src activation, which is one of the cellular
events associated with oncogenic transformation.
pharmacological compounds (35, 53–58). Of strong interest for
clinical applications, in vivo studies have also demonstrated that
Src inhibition is able to provoke decreased tumoral xenograft
growth by reducing angiogenesis (50, 56).
Src AND PROSTATE CANCER METASTASES
Advanced PCa is frequently associated with metastases. The tumor
metastatic cascade includes several steps from the detachment of
isolated cells with survival capability from the primary tumor,
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Table 2 | Representative studies that evaluated the biological effects of Src inhibitors on basic cellular events associated with prostate cancer
progression.
Reference Cell lines Inhibitors Decreased proliferation Decreased
migration
Decreased
adhesion
Apoptosis Decreased tumoral
xenograft growth
(45) DU-145 PD173955 Yes – – – –
(36) DU-145 PP2 – Yes – – –
PC-3
LNCaP
(46) PC-3 CGP77675 Yes Yes Yes No –
CGP76080
(47) PC-3 Compound 1 Yes – – – –
(5) DU-145 Lyn-inhibiting peptides Yes – – Yes Yes
PC-3
(6) DU-145 Dasatinib – Yes Yes – –
(23) LNCaP PP1 Yes (androgen-dependent
proliferation)
– – – –
(32) PC-3 SI35 Yes Yes Yes – –
SI40
(48) DU-145 Resveratrol Yes – – Yes –
(9) DU-145 Saracatinib Yes Yes – – Yes
PC-3
(43) PC-3-MM32GL Dasatinib Yes Yes – Yes Yes (and decreased
lymphatic spread)PC-3-AR-A1
LNCaP
(49) DU-145 Bosutinib Yes Yes Yes – Yes (and decreased bone
metastases)PC-3
(50) DU-145 Dasatinib Yes Yes – – Yes (and decreased
angiogenesis)PC-3
LNCaP
(44) CWR22 Dasatinib – – – – Yes (androgen-independent
growth)KX01
(33) PC-3 Dasatinib – Yes – – –
(51) PC-3 CTA095 Yes Yes – Yes Yes
their migration through the vascular endothelium into the blood
stream, their extravasation from the blood stream to the receiv-
ing tissue, and the local development of the secondary tumor. To
migrate through stromal tissue and invade an adjacent blood ves-
sel, the tumor cell has to develop the ability to survive as an isolated
cell, devoid of all contact with other cells and the base membrane.
This survival depends on the acquisition of resistance to anoikis,
i.e., the variety of apoptosis induced by the loss of the close con-
tacts established between an epithelial cell and the base membrane.
Mobility, invasion, and resistance to anoikis are an integral part of
a general phenomenon known as the epithelium-to-mesenchyme
transition (EMT) (59). EMT is a biological process by which a
tumor cell loses some of the features of an epithelial cell (e.g.,
expression of epithelial markers such as E-cadherin) and acquires
some of the characteristics of a mesenchymal cell (expression
of mesenchymal markers such as N-cadherin). Through inter-
actions with “true” mesenchymal cells, the modified cell migrates
more easily through the stroma. EMT is actually a physiological,
evolutionary-conserved process that takes place during normal
embryonic and fetal development (gastrulation and morphogen-
esis) and in some adult situations (wound healing and tissue
regeneration) (60, 61). EMT is considered to be the first step of
metastatic spread (60), and cells engaged in this process are located
at the invasion front (62). Within the metastatic site, a mirror
process occurs, whereby the secondary tumor develops like the
primary one, including with respect to more or less differentiated
www.frontiersin.org August 2014 | Volume 4 | Article 222 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vlaeminck-Guillem et al. Src and prostate cancer agressiveness
epithelial cells (mesenchyme-to-epithelium transition) (63). EMT,
or at least EMT-like states, has been described in PCa (59).
An archetypal phenomenon associated with EMT, namely, the
so-called cadherin switch from the epithelial E-cadherin to the
mesenchymal N-cadherin, is of biological importance as the loss
of E-cadherin is associated with the loss of cell-cell junctions.
E-cadherin expression is therefore tightly regulated and is notably
under the control of EMT-specific transcription factors such as
Snail, Slug, Twist, and Zeb1/2. Src activation is known as a potent
inducer of EMT and has been proved to induce the dissocia-
tion of the complex between E-cadherin and beta-catenin through
E-cadherin phosphorylation (39, 64). As a first testimony of Src
implication in PCa-associated EMT, decreased E-cadherin expres-
sion and increased N-cadherin expression have been linked to Src
activation in PCa cells (49, 65–67). Although a detailed and direct
demonstration of Src as an inducer of EMT in PCa is still lacking,
a few studies support the Src implication by showing a corre-
lation between Src activation and the markers of EMT, such as
the mesenchymal aspect of epithelial cells (65), the expression of
vimentin (67–69), the action of EMT inducers (70), the expression
of EMT-specific transcription factors (65) or micro-RNAs (25, 67),
or the EMT-associated increase in cell proliferation, invasion, or
mobility (65, 69).
Of note is the fact that EMT is one of the aspects of a larger
phenomenon called epithelial plasticity (71). Epithelial plasticity
refers to the capacity of cells to undergo reversible phenotypic
changes during cell invasion or spread. In other words, the epithe-
lial phenotype is partly lost and replaced by another phenotype,
for example a mesenchymal one during EMT. The acquisition of
stemness characteristics can be regarded as epithelial plasticity. For
PCa, other more specific phenotypes are neuroendocrine differen-
tiation (NED) (72, 73) and osteomimicry (74, 75). These various
phenotypes represent the Darwinian adaptation of cancer cells
to their environment, are usually transient, and are not mutually
exclusive. In a recently published model of EMT induction in PC-3
cells by the inactivation of the E-cadherin gene, expression of stem-
ness, NED, and osteomimicry markers was indeed simultaneously
observed (69). While NED is usually induced by androgen depri-
vation (see below), osteomimicry is a means by which metastatic
PCa cells adapt to the bone environment (74–77).
Bones are actually the main metastasis site for PCa cells, which
have been shown to deregulate the normal remodeling process
that assures bone maintenance. They secrete several molecules
such as growth factors and cytokines that alter the tight interplay
between osteoclasts and osteoblasts. The balance is in favor of
osteoblastogenesis, which explains the usual condensing aspect of
PCa-derived bone metastases. Src signaling is a key pathway for
bone remodeling regulation, and several lines of evidence link it to
the bone metastatic process (78). Several cell models of PCa have
linked Src activation with the ability to develop distant metastases
(43, 49), while various animal studies also demonstrated the effi-
ciency of Src inhibitors when it comes to reducing bone metastases
due to PCa (79–82).
Src therefore seems to be implicated in two crucial steps of the
PCa metastatic process: EMT and the consequent cell ability to
detach from the primary tumor, and local development of the sec-
ondary tumor within the metastatic site. It is also worth noting
that the initial arrest and adhesion of cancer cells to the vascular
endothelium is also an essential step, being intermediary between
the two steps referred to, preceding their extravasation from the
blood stream. As well as its role in promoting angiogenesis (see
above), Src has also been revealed to play a part in the endothelial
permeability that permits cancer cell extravasation (83). In PCa
cells, the activated transcription factor Stat5 induces decreased E-
cadherin expression as well as the increased adhesion of PCa cells
to endothelial cells (84). This effect is inhibited by the Src inhibitor
PP2, suggesting that Src also mediates endothelial permeability in
PCa (84).
Src, NEUROENDOCRINE DIFFERENTIATION, AND
RESISTANCE TO CASTRATION
The development of the embryonic prostate gland and the main-
tenance of the adult one are very dependent on androgen stimu-
lation. At least during the initial stages of prostate carcinogenesis,
PCa cells are naturally androgen-dependent. Androgen depriva-
tion consequently became the first choice treatment for PCas that
could not be physically and locally cured. Resistance to castration
is the ability of PCa cells to escape and survive, despite androgen
deprivation. As the main cause of PCa-related deaths, resistance
to castration has been extensively studied and several mechanisms
have been advocated such as AR overexpression, AR activation by
non-androgenic ligands (because of specific gene mutations that
alter the specificity of the ligand binding), or the activation of
AR-bypassing signaling pathways (85). Another significant mech-
anism is AR activation in the absence of any ligand (85). During
this process, the AR is subverted through activation by several
soluble factors, essential growth factors such as EGF or IGF-1.
These factors act by inducing phosphorylation cascades from their
TK membrane receptors. As an integrator of several phosphoryla-
tion cascade-inducing extracellular signals, Src has logically been
advocated as one of the intermediate effectors that transmit the
activation signals from growth factors to the AR pathway.
Indeed,a direct physical interaction has been described between
Src and the AR (Figure 2). The AR contains a proline-rich region,
which has a clear affinity for the Src SH3 domain (19). This interac-
tion is able to relieve Src folding constraints and therefore induces
Src activation. Androgens favor the formation of the AR–Src com-
plex, stimulate the Src/Raf-1/Erk-2 pathway,and consequently lead
to the increased proliferation of PCa cells (19, 20). Such an inter-
action is likely to augment the Src oncogenetic effect in prostate
cells (17, 18). It should be noted that AR and Src in fact engage in
a ternary complex with the estrogen receptor (ER). Complex for-
mation is therefore favored by either androgens or estrogens and
conversely inhibited by antiandrogens or antiestrogens. While the
AR interacts with the Src SH3 domain, the ER interacts with the
SH2 domain (19). Other partners include TK membrane recep-
tors such as IGF1-R that can be overexpressed and activated by
AR-stimulated Src (86).
The interaction between the AR and Src not only favors Src
activation but also AR activation (Figure 2). It is well known that
AR phosphorylation is implicated in AR translocation from the
cytoplasm to the nucleus (8), and its transcriptional activity (8,
87–89). A correlation has been demonstrated between AR expres-
sion or activity and Src activation in PCa (8, 21, 90). The tyrosine
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Y534 in the AR would be the Src target (17, 19, 21, 91) and its
phosphorylation would result in ligand-independent AR activa-
tion, which is an important mechanism to explain resistance to
castration. Activated Src would also inhibit AR interaction with co-
repressors, thereby increasing its capacity to be activated without
ligand binding (92).
The AR–Src is a target for several signals that thereby influence
Src and/or AR activation. The product of the tumor-suppressor
gene DOC2/DAB2 is able to repress PCa cell proliferation through
direct interaction with Src and the inhibition of the complex for-
mation (23). The EGF/EGFR pathway activates Src in LNCaP cells
that are cultured without androgens, probably through the stim-
ulation of the AR–Src complex formation (93, 94). The use of an
antiandrogen does indeed block the proliferative effect, underly-
ing the role of the AR as a downstream effector of the EGF/EGFR
pathway (93). Similar actions of several other growth factors are
likely since many other receptors are expressed in PCa and are able
to interact with and activate Src (95). Finally, the AR gene seems
to be able to produce a splice variant, called AR8, which lacks the
DNA-binding domain, and is instead located at the plasma mem-
brane and favors interactions between the full-length AR, Src, and
EGFR (96).
Resistance to hormone castration is often linked to NED, since
NED is almost always the result of androgen deprivation (72, 73).
NED is characterized by the production of neuropeptides such
as chromogranine A, NSE, serotonin, neurophysin, and synapto-
physin. All of these products are thought to exert paracrine effects
on adjacent (epithelial) cells, keeping them alive despite andro-
gen deprivation (3). Bombesin is another secreted neuropeptide.
Bound to its membrane receptor, it activates Src and thus favors
AR phosphorylation and its androgen-independent activation (26,
90). The same action is suggested for other neuropeptides such
as neurotensin (26, 27), PTHrp (97), and gastrin-releasing pep-
tide (98). It is, however, still unclear whether these neuropeptides
directly activate Src or activate it by stimulating the EGF/EGFR
pathway and interactions between Src and EGFR (22, 27, 96, 97).
Similar complex interactions could also be observed between the
neuropeptides, Src, the AR, and the IGF1-R (28). Another molecu-
lar mechanism by which bombesin activates the AR has been sug-
gested: the bombesin is able to stimulate, via Src, p300-mediated
AR acetylation (99).
Src INHIBITORS IN CLINICAL PRACTICE
As described above, several experimental studies performed in cel-
lulo or in animal models of PCa suggested that molecules able to
inhibit Src and/or other members of the SFK could be of clinical
interest. Several phase I and phase II clinical trials have therefore
been conducted to assess tolerance, side-effects, and optimal dose
for three of the several orally bioavailable Src inhibitors: dasatinib
(BMSS354825), saracatinib (AZD0530), and KX2-391. The first
two act by directly inhibiting the TK activity while the third acts
through inhibition of protein–protein interactions. Results were
disappointing when saracatinib and KX2-391 were assessed as
monotherapy in phase II trials that accrued patients with metasta-
tic CRPC (100, 101). Dasatinib is the most clinically studied
SFK inhibitor and has been assessed in several cancers includ-
ing liquid and solid tumors. It is currently FDA-approved for
chronic myelogenous leukemia and, as a second line treatment, for
Philadelphia chromosome-positive acute lymphoblastic leukemia.
In PCa, dasatinib reached phase II development programs as
monotherapy in chemotherapy-naïve men (102, 103), and in men
previously treated with one chemotherapy regimen (104), or in
association with the cytotoxic docetaxel (105, 106). The relative
efficacy of dasatinib (102, 103, 105) and the description of patients
with long term survival (104, 106) prompted clinicians to perform
phase III trial comparing docetaxel+ prednisolone with either
dasatinib or placebo (107). Results of this large trial (more than
1500 patients accrued) were disappointing in that the addition of
dasatinib did not perform better than docetaxel+ prednisolone
in terms of overall survival. This failure can be explained by
several factors including inadequate study design (108), poten-
tial pharmacokinetic interactions between dasatinib and docetaxel
(109), a stronger effect on stromal cells than on epithelial cells
(despite association with the epithelial-targeted docetaxel), and the
too broad specificity of inhibitory effect of dasatinib for numer-
ous receptor and non-receptors TK. Subsequent clinical trials are
therefore warranted, which have to be based on an comprehensive
knowledge about the optimal timing of a Src inhibitor strategy
in PCa progression (before or after chemotherapy? before or after
metastatic spreading? . . .), the intrinsic biology of the patient’s
tumor and the value of its association with other new therapeutic
agents such as antiangiogenic factors (110).
CONCLUSION
Overall, Src has been implicated in several steps of prostate car-
cinogenesis. It is likely that it plays similar, major roles in other
cancers. The particularity of the Src oncogenic action in prostate
carcinogenesis is its ability to interfere with the androgen path-
way. Through both direct and indirect interaction with the AR,
Src is able to reinforce the proliferative and antiapoptotic actions
of the AR, even in the absence of specific ligands. These molecular
mechanisms constitute a solid rationale in favor of the use of Src
inhibitors in routinely managing patients with PCa.
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